BioVenture VoiCes with Chris Garabedian Episode 37: SR One's Simeon George
Mar 23, 2026
Simeon George, CEO and co-founder of SR One and physician-turned-investor, led its spinout from GSK and builds biotech companies. He recounts SR One’s transition to independence, how they pick and reserve capital for bets across modalities and indications, and the role of collaboration and syndication in sourcing and scaling ventures. He also touches on global sourcing, selective tech bets, and how AI fits into R&D.
AI Snips
Chapters
Transcript
Episode notes
Contrarian Investing During Downturns
- Under Andrew Witty SR One was elevated to report to the CEO, expand check sizes and act more catalytically during risk-off markets.
- That contrarian deployment during downturns became a core learning and advantage.
Financial First With Strategic Visibility
- SR One maintained a separation of church and state: the firm pursued financial returns while providing GSK strategic visibility without being directive.
- The model gave GSK ecosystem insights while preserving SR One's independent fiduciary duty.
Spinout Fueled By Founder Ambition And Corporate Rebalance
- Simeon led SR One's spinout driven by his desire for autonomy after founding companies and a corporate reassessment of SR One's strategic benefit to GSK.
- GSK became anchor LP post-spinout and SR One kept the name and heritage.